BACKGROUND: There is scarce data on the outcome of young patients aged 35 years and younger, who have been treated with neoadjuvant chemotherapy. The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer. PATIENTS AND METHODS: This is a retrospective evaluation on the outcome of 110 patients who were younger than 35 years at diagnosis and treated with neoadjuvant chemotherapy (CT). Patients were grouped in quartiles of BMI calculated prior to initiation of chemotherapy. Logistic regression analysis was performed to investigate the associations between prognostic variables including BMI and treatment outcome. The impact of prognostic factors on survival was analyzed by Kaplan-Maier and Cox regression tests. RESULTS: Body mass index was not correlated with pathologic complete response (pCR) (n = 13, 11.7%) or survival. Cox regression analysis revealed nodal pCR following neoadjuvant chemotherapy (HR 2.45, P = 0.048) and stage at diagnosis (HR1.99, P = 0.027) as significant independent prognostic factors for DFS, while recurrence was independently associated with shorter OS (HR 169, P = 0.029). CONCLUSION: Body mass index was not correlated with pCR or prognosis in young women with early breast cancer. Pathologic CR was shown to have a significant influence on DFS. Total axillary clearance may be used a surrogate variable in determining prognosis in young patients treated with neoadjuvant chemotherapy.
BACKGROUND: There is scarce data on the outcome of young patients aged 35 years and younger, who have been treated with neoadjuvant chemotherapy. The aim of this study is to evaluate the impact of body mass index (BMI) and various prognostic factors on pathologic response and survival in young patients with localized breast cancer. PATIENTS AND METHODS: This is a retrospective evaluation on the outcome of 110 patients who were younger than 35 years at diagnosis and treated with neoadjuvant chemotherapy (CT). Patients were grouped in quartiles of BMI calculated prior to initiation of chemotherapy. Logistic regression analysis was performed to investigate the associations between prognostic variables including BMI and treatment outcome. The impact of prognostic factors on survival was analyzed by Kaplan-Maier and Cox regression tests. RESULTS: Body mass index was not correlated with pathologic complete response (pCR) (n = 13, 11.7%) or survival. Cox regression analysis revealed nodal pCR following neoadjuvant chemotherapy (HR 2.45, P = 0.048) and stage at diagnosis (HR1.99, P = 0.027) as significant independent prognostic factors for DFS, while recurrence was independently associated with shorter OS (HR 169, P = 0.029). CONCLUSION: Body mass index was not correlated with pCR or prognosis in young women with early breast cancer. Pathologic CR was shown to have a significant influence on DFS. Total axillary clearance may be used a surrogate variable in determining prognosis in young patients treated with neoadjuvant chemotherapy.
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Miguel Martin; Tadeusz Pienkowski; John Mackey; Marek Pawlicki; Jean-Paul Guastalla; Charles Weaver; Eva Tomiak; Taher Al-Tweigeri; Linnea Chap; Eva Juhos; Raymond Guevin; Anthony Howell; Tommy Fornander; John Hainsworth; Robert Coleman; Jeferson Vinholes; Manuel Modiano; Tamas Pinter; Shou C Tang; Bruce Colwell; Catherine Prady; Louise Provencher; David Walde; Alvaro Rodriguez-Lescure; Judith Hugh; Camille Loret; Matthieu Rupin; Sandra Blitz; Philip Jacobs; Michael Murawsky; Alessandro Riva; Charles Vogel Journal: N Engl J Med Date: 2005-06-02 Impact factor: 91.245
Authors: Ian C Smith; Steven D Heys; Andrew W Hutcheon; Iain D Miller; Simon Payne; Fiona J Gilbert; Antoinne K Ah-See; Oleg Eremin; Leslie G Walker; Tarun K Sarkar; S Peter Eggleton; Keith N Ogston Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: G Berclaz; S Li; K N Price; A S Coates; M Castiglione-Gertsch; C-M Rudenstam; S B Holmberg; J Lindtner; D Erien; J Collins; R Snyder; B Thürlimann; M F Fey; C Mendiola; I Dudley Werner; E Simoncini; D Crivellari; R D Gelber; A Goldhirsch Journal: Ann Oncol Date: 2004-06 Impact factor: 32.976
Authors: J Y Pierga; E Mouret; V Diéras; V Laurence; P Beuzeboc; T Dorval; T Palangié; M Jouve; A Vincent-Salomon; S Scholl; J M Extra; B Asselain; P Pouillart Journal: Br J Cancer Date: 2000-12 Impact factor: 7.640
Authors: Haiyun Wang; Shijia Zhang; Douglas Yee; Saonli Basu; Heather Beckwith; David Potter; Anne Blaes Journal: Breast Cancer Date: 2021-01-02 Impact factor: 4.239
Authors: Laura M Spring; Geoffrey Fell; Andrea Arfe; Lorenzo Trippa; Aditya Bardia; Chandni Sharma; Rachel Greenup; Kerry L Reynolds; Barbara L Smith; Brian Alexander; Beverly Moy; Steven J Isakoff; Giovanni Parmigiani Journal: Clin Cancer Res Date: 2020-02-11 Impact factor: 12.531
Authors: D S M Chan; A R Vieira; D Aune; E V Bandera; D C Greenwood; A McTiernan; D Navarro Rosenblatt; I Thune; R Vieira; T Norat Journal: Ann Oncol Date: 2014-04-27 Impact factor: 32.976